UA110935C2 - Sustained-release insulin formulation - Google Patents

Sustained-release insulin formulation

Info

Publication number
UA110935C2
UA110935C2 UAA201214529A UAA201214529A UA110935C2 UA 110935 C2 UA110935 C2 UA 110935C2 UA A201214529 A UAA201214529 A UA A201214529A UA A201214529 A UAA201214529 A UA A201214529A UA 110935 C2 UA110935 C2 UA 110935C2
Authority
UA
Ukraine
Prior art keywords
sustained
insulin formulation
release insulin
release
formulation
Prior art date
Application number
UAA201214529A
Other languages
Ukrainian (uk)
Inventor
Райнхард БЕККЕР
Аннке Фрік
Петер БОДЕРКЕ
Крістіане Фюрст
Вернер Мюллер
Катрін Терч
Ульріх Вернер
Петра ЛООС
Ізабелль Шеттлє
Original Assignee
Санофі
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофі filed Critical Санофі
Priority claimed from PCT/EP2011/058079 external-priority patent/WO2011144673A2/en
Publication of UA110935C2 publication Critical patent/UA110935C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

Винахід стосується водного фармацевтичного препарату, що містить 270-330 Од/мл інсуліну гларгіну [еквімолярно 270-330 МО людського інсуліну], а також його застосування.The invention relates to an aqueous pharmaceutical preparation containing 270-330 IU / ml insulin glargine [equimolar to 270-330 IU human insulin], and its use.

UAA201214529A 2010-05-19 2011-05-18 Sustained-release insulin formulation UA110935C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305532 2010-05-19
PCT/EP2011/058079 WO2011144673A2 (en) 2010-05-19 2011-05-18 Long - acting formulations of insulins

Publications (1)

Publication Number Publication Date
UA110935C2 true UA110935C2 (en) 2016-03-10

Family

ID=42643093

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201214529A UA110935C2 (en) 2010-05-19 2011-05-18 Sustained-release insulin formulation

Country Status (1)

Country Link
UA (1) UA110935C2 (en)

Similar Documents

Publication Publication Date Title
PH12019500517A1 (en) Long-acting formulations of insulins
CY1119058T1 (en) IMIDAZOPYRROLIDINONE COMPOUNDS
UY34350A (en) DERIVATIVES OF PIRAZOLQUINOLINONA, ITS PREPARATION AND THERAPEUTIC USE.
MX2016005395A (en) Stable formulation of insulin glulisine.
EA201590797A1 (en) PREPARATIONS WITH THE MODIFIED PROBE RELEASE
PH12014502856A1 (en) Solid pharmaceutical preparation containing levothyroxine
TR200909785A1 (en) Pharmaceutical compositions containing cefdinir as the active agent.
TR200904500A2 (en) Methods and pharmaceutical formulations for the preparation of ezetimibe nanocrystals.
UA110935C2 (en) Sustained-release insulin formulation
EA201491991A1 (en) NEW SYSTEM FOR THE HYDROPHOBIC PROTEINS
EA201590732A1 (en) DISPENSABLE TABLET
TR201009399A2 (en) Rapidly soluble effervescent rosuvastatin formulations.
TR201009395A2 (en) Effervescent formulations with improved taste.
TR201203085A2 (en) Compositions containing sefetamet and clavulanic acid.
TR201203086A2 (en) Pharmaceutical dosage form comprising cefixime and clavulanic acid.
JO3497B1 (en) Pharmaceutical preparation comprising recombinant hcg
TR201203083A2 (en) Pharmaceutical dosage form comprising cefdinir and clavulanic acid.
TR201005911A2 (en) A drug formulation with improved dissolution profile.
TR200806299A2 (en) Solubility enhancing pharmaceutical formulation
EA201101703A1 (en) 17β-ALKYL-17α-OXYESTRATRIENES
UA111824C2 (en) MEDICINAL FORMS OF RIFAXIMINE AND THEIR APPLICATIONS
RU2011124335A (en) VITAMIN DRUG